UBS Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $72
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
Merus Is Maintained at Buy by Guggenheim
Merus Analyst Ratings
BMO Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $95
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
Buy Rating Affirmed for Merus on Strong Clinical Trial Progress and Competitive Positioning
Truist Financial Maintains Merus(MRUS.US) With Buy Rating
Truist Financial Gives a Buy Rating to Merus (MRUS)
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $100
Buy Rating on Merus Backed by Strong Clinical Advantages and Market Positioning
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Analysts Conflicted on These Healthcare Names: Merus (MRUS), Staar Surgical (STAA) and Rani Therapeutics Holdings (RANI)
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Brookdale Senior Living (BKD) and Arrowhead Pharmaceuticals (ARWR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Needham Maintains Merus(MRUS.US) With Buy Rating, Cuts Target Price to $85
Merus Analyst Ratings
Buy Rating Affirmed for Merus on Strong Clinical Progress and Capital Raise